The Uromigos Episode 67: The Third Debate—PD1/VEGF Versus PD1/CTLA4 for Front-Line Renal Cancer

Drs. David McDermott and Brian Rini debate treatment options (PD1/VEGF versus PD1/CTLA4) in front-line renal cancer. It’s hard to identify any winners from this podcast.

Related Episodes

Episode 196: The COSMIC-313 Trial Cabo/Ipi/Nivo in First-Line Renal Cancer
Episode 99: Navigating Social Media From a Patients’ Perspective
Episode 186: Bernard Escudier—The Uromigos Legends Series
Episode 182: ASCO Kidney Cancer Guidelines
The Uromigos Episode 168: Mechanisms of Response to PD1 Therapy in Renal Cancer
The Uromigos Episode 167: Highlights from EIKCS Oral Session
The Uromigos Episode 163: Debate—Treatment of Favorable Risk Renal Cancer
The Uromigos Episode 162: Debate—Adjuvant Nivolumab for Bladder Cancer
The Uromigos Episode 150: Comparing the Quality of Life Data in Renal Trials
The Uromigos Episode 149: Treatment-Free Survival for Ipilimumab and Nivolumab